Spots Global Cancer Trial Database for rad001
Every month we try and update this database with for rad001 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| RAD001 Plus Bevacizumab in Metastatic Melanoma | NCT00591734 | Metastatic Mela... | Bevacizumab Everolimus | 18 Years - | SCRI Development Innovations, LLC | |
| Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer | NCT00892801 | Lung Cancer Metastatic Canc... | RAD001 whole-brain rad... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium | NCT00805129 | Bladder Cancer Metastatic Tran... | Everolimus | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| RAD001 and Bicalutamide for Androgen Independent Prostate Cancer | NCT00630344 | Prostate Cancer | RAD001 Bicalutamide | 18 Years - | Dana-Farber Cancer Institute | |
| Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma | NCT01491672 | Metastatic Rena... | RAD001 | 18 Years - | Novartis | |
| RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN | NCT01009346 | Head and Neck C... | RAD001 Cetuximab Cisplatin Carboplatin | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) | NCT00789828 | Tuberous Sclero... Subependymal Gi... | Everolimus Placebo | - | Novartis | |
| Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer | NCT00522665 | Colorectal Canc... | Irinotecan Cetuximab RAD001 | 18 Years - | Hoosier Cancer Research Network | |
| Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT00124280 | Non-small-cell ... | RAD001 | 18 Years - | Novartis | |
| Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) | NCT00790400 | Tuberous Sclero... Lymphangioleiom... | Everolimus (RAD... Everolimus Plac... | 18 Years - | Novartis | |
| Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT00124280 | Non-small-cell ... | RAD001 | 18 Years - | Novartis | |
| Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. | NCT01035229 | Carcinoma | Everolimus Everolimus Plac... Best Supportive... | 18 Years - | Novartis | |
| Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas | NCT00782626 | Glioma Low-grade Gliom... Astrocytoma | everolimus | 3 Years - 21 Years | Dana-Farber Cancer Institute | |
| RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms | NCT00927966 | Sarcoma Solid Tumor | RAD001 CP-751,871 | 18 Years - | Dana-Farber Cancer Institute | |
| Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer | NCT00317720 | Breast Cancer Neoplasm Metast... | Trastuzumab RAD001 | 18 Years - | M.D. Anderson Cancer Center | |
| Study of RAD001 in Adenoid Cystic Carcinoma | NCT01152840 | Adenoid Cystic ... | RAD001 | 18 Years - | Seoul National University Hospital | |
| Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | NCT01596140 | Advanced Cancer Solid Tumor | Vemurafenib Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy | NCT01248403 | Advanced Gastri... Esophagogastric... | Paclitaxel RAD001 | 18 Years - | Krankenhaus Nordwest | |
| A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma | NCT01797523 | Endometrial Can... | Metformin Letrozole Everolimus | 18 Years - | M.D. Anderson Cancer Center | |
| Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas | NCT01048723 | Sarcoma | RAD001 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma | NCT01510119 | Metastatic Clea... | Hydroxychloroqu... RAD001 | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma | NCT01185366 | Kidney Cancer | Everolimus Sunitinib | 18 Years - | M.D. Anderson Cancer Center | |
| RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX | NCT01049620 | Advanced Gastri... | RAD001, Capecit... | 18 Years - 70 Years | Asan Medical Center | |
| RAD001 Plus Bevacizumab in Metastatic Melanoma | NCT00591734 | Metastatic Mela... | Bevacizumab Everolimus | 18 Years - | SCRI Development Innovations, LLC | |
| Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients | NCT01490476 | Neurofibromatos... | RAD001 | 15 Years - | Assistance Publique - Hôpitaux de Paris | |
| Exemestane-RAD001-Metformin | NCT01627067 | Breast Cancer | Everolimus Exemestane Metformin | 18 Years - | M.D. Anderson Cancer Center | |
| A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy | NCT00714025 | Transitional Ce... | RAD001 | 18 Years - | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | |
| A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures | NCT01713946 | Tuberous Sclero... | RAD001 Placebo Antiepileptic d... open label RAD0... | 2 Years - 65 Years | Novartis | |
| A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors | NCT00985374 | Neoplasms | RAD001 RG1507 | 18 Years - | Hoffmann-La Roche | |
| Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | NCT01087554 | Advanced Cancer | Sirolimus Vorinostat Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma | NCT00323739 | Kidney Cancer | bevacizumab RAD001 | 18 Years - | SCRI Development Innovations, LLC | |
| Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease | NCT01864070 | Liver Cancer | TheraSphere Everolimus Phone Call | 18 Years - | M.D. Anderson Cancer Center | |
| Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer | NCT00446368 | Carcinoma, Rena... | RAD001 | 18 Years - | The Methodist Hospital Research Institute | |
| Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | NCT00804336 | Neuroendocrine ... Carcinoid Tumor Pancreatic Neur... | SOM230 RAD001 | 18 Years - | Dana-Farber Cancer Institute | |
| RAD001 for Patients With Radioiodine Refractory Thyroid Cancer | NCT00936858 | Thyroid Cancer | RAD001 | 18 Years - | Dana-Farber Cancer Institute | |
| Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | NCT01087554 | Advanced Cancer | Sirolimus Vorinostat Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | NCT01596140 | Advanced Cancer Solid Tumor | Vemurafenib Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma | NCT01525719 | Cholangiocarcin... | Everolimus | 18 Years - | Ratchavithi Hospital | |
| Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor | NCT01324492 | Lung Neuroendoc... | RAD001 | 18 Years - 80 Years | Novartis | |
| Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs | NCT01590199 | Neuroendocrine ... | RAD001 SOM230 | 18 Years - | Novartis | |
| Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer | NCT01184326 | Solid Tumor Kidney Cancer | pazopanib everolimus | 18 Years - | Dana-Farber Cancer Institute | |
| Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer | NCT00574366 | Breast Cancer | erlotinib RAD001 | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers | NCT00703807 | Endometrial Can... | Topotecan RAD001 | 18 Years - | Yale University | |
| RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma | NCT00729638 | Multiple Myelom... | RAD001 lenalidomide | 18 Years - | Massachusetts General Hospital | |
| Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast | NCT00473005 | Breast Cancer | Capecitabine RAD001 | 18 Years - | Stanford University | |
| Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer | NCT00967928 | Cervical Cancer | RAD001 Cisplatin External Beam W... | 18 Years - | Accelerated Community Oncology Research Network | |
| RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment | NCT00729482 | Stomach Neoplas... | RAD001 | 18 Years - 75 Years | Asan Medical Center | |
| Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. | NCT01035229 | Carcinoma | Everolimus Everolimus Plac... Best Supportive... | 18 Years - | Novartis | |
| The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer | NCT00459186 | Metastatic, And... Prostate Cancer | RAD001 Docetaxel Prednisone | 18 Years - | Dana-Farber Cancer Institute | |
| LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma | NCT02138929 | Esophageal Canc... | Everolimus LDE 225 | 18 Years - | M.D. Anderson Cancer Center | |
| RAD001 in Advanced Sarcoma | NCT01830153 | Soft Tissue Sar... Bone Sarcomas | RAD001 | 17 Years - | Asan Medical Center | |
| Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium | NCT00805129 | Bladder Cancer Metastatic Tran... | Everolimus | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer | NCT00448149 | Carcinoma, Rena... | RAD001 Sorafenib | 18 Years - | The Methodist Hospital Research Institute | |
| Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | NCT01125293 | Waldenstrom's M... | Everolimus Rituximab Bortezomib | 18 Years - | Dana-Farber Cancer Institute | |
| RAD001 and Bicalutamide for Androgen Independent Prostate Cancer | NCT00630344 | Prostate Cancer | RAD001 Bicalutamide | 18 Years - | Dana-Farber Cancer Institute | |
| Phase II Study of RAD001 Head and Neck Cancer | NCT01051791 | Squamous Cell C... | Everolimus 10mg... | 18 Years - 80 Years | University of Pittsburgh | |
| A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma | NCT00422344 | Renal Cell Carc... Kidney Cancer | RAD001, Sunitin... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety of Everolimus and Pemetrexed in Lung Cancer Patients | NCT00434174 | Non Small Cell ... | Everolimus Pemetrexed | 18 Years - | Novartis | |
| RAD001 in Recurrent Endometrial Cancer Patients | NCT00087685 | Endometrial Can... | RAD001 | - | M.D. Anderson Cancer Center | |
| RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma | NCT00113360 | Neuroendocrine ... Islet Cell Carc... | RAD001 Octreotide Depo... | 18 Years - | M.D. Anderson Cancer Center | |
| Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer | NCT00392821 | Kidney Cancer | Sorafenib RAD001 | 18 Years - | SCRI Development Innovations, LLC | |
| Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas | NCT01880749 | Neurofibromatos... Vestibular Schw... Meningiomas | RAD001 | 18 Years - | NYU Langone Health | |
| Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | NCT00978432 | Diffuse Large B... | RAD001 LBH589 Doublet (RAD001... | 18 Years - | Duke University | |
| RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors | NCT00576680 | Pancreatic Neur... | RAD001 Temozolomide | 18 Years - | Dana-Farber Cancer Institute | |
| Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas | NCT01880749 | Neurofibromatos... Vestibular Schw... Meningiomas | RAD001 | 18 Years - | NYU Langone Health | |
| RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. | NCT01188889 | Chronic Myeloid... | RAD001 Imatinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer | NCT00458237 | Breast Cancer | Everolimus Trastuzumab | 18 Years - | Dana-Farber Cancer Institute | |
| RAD001 and Erlotinib in Patients With Neuroendocrine Tumors | NCT00843531 | Neuroendocrine ... | RAD001 erlotinib | 18 Years - | University of California, San Francisco | |
| Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer | NCT01068249 | Endometrial Can... | Letrozole RAD001 (Everoli... | 18 Years - | M.D. Anderson Cancer Center | |
| Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer | NCT00406276 | Lung Cancer | RAD001 Docetaxel | 18 Years - | Emory University | |
| Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer | NCT01490749 | Esophageal Canc... Neoplasms, Esop... | RAD001 XELOX Carboplatin Radiation | 18 Years - | Emory University | |
| RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid | NCT01152827 | Pheochromocytom... Extra-adrenal P... Non-functioning... | RAD001 | 18 Years - | Seoul National University Hospital | |
| Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer | NCT00574769 | Prostate Cancer | RAD001, Docetax... | 18 Years - | University of Southern California | |
| Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex | NCT01730209 | Tuberous Sclero... TSC Related Cog... TSC Related Aut... TSC Related Lea... | Everolimus Placebo | 4 Years - 15 Years | Erasmus Medical Center | |
| A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer | NCT01283334 | Head and Neck N... Cancer of the H... | Carboplatin Cetuximab RAD001 | 18 Years - | Emory University | |
| The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer | NCT00459186 | Metastatic, And... Prostate Cancer | RAD001 Docetaxel Prednisone | 18 Years - | Dana-Farber Cancer Institute | |
| Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia | NCT00636922 | Acute Myeloid L... | RAD001(Everolim... | 18 Years - | Bayside Health | |
| A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma | NCT00788060 | Renal Cell Carc... | Everolimus (RAD... Sunitinib (Sute... | 18 Years - | Duke University | |
| RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma | NCT01047293 | Colorectal Canc... | RAD001 FOLFOX Bevacizumab | - | University of Utah | |
| A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy | NCT01248403 | Advanced Gastri... Esophagogastric... | Paclitaxel RAD001 | 18 Years - | Krankenhaus Nordwest |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
